Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.36, Zacks reports. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.01 million. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 18,150.00%.
Cyclacel Pharmaceuticals Price Performance
Shares of CYCC traded down $0.04 during trading hours on Thursday, hitting $0.41. 507,616 shares of the company were exchanged, compared to its average volume of 711,483. The firm has a fifty day simple moving average of $0.88 and a 200-day simple moving average of $1.44. The company has a market capitalization of $881,285.00, a PE ratio of -0.05 and a beta of 0.56. Cyclacel Pharmaceuticals has a one year low of $0.37 and a one year high of $6.00.
Analyst Ratings Changes
A number of research firms recently issued reports on CYCC. StockNews.com assumed coverage on Cyclacel Pharmaceuticals in a report on Thursday, November 7th. They set a “sell” rating on the stock. Roth Capital cut shares of Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
Read More
- Five stocks we like better than Cyclacel Pharmaceuticals
- Find and Profitably Trade Stocks at 52-Week Lows
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- What Investors Need to Know About Upcoming IPOs
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- What is the Australian Securities Exchange (ASX)
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
